Monitor upcoming WRAP North America registry results and quarterly revenue disclosures for WRAPSODY sales traction. The positive real-world data may support gradual market share gains in dialysis access, but the product is already approved and launched, so this is an incremental clinical validation event.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $89.62entry
- T+1 · 11d ago −2.67%α −2.98% · $87.23
- T+5 · 5d ago −3.27%α −6.56% · $86.69
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Merit Medical announced positive 6-month real-world patency results from the AVF cohort of the WRAPSODY Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency, both slightly higher than the pivotal WAVE trial. The data, presented at CiDA 2026, reinforce physician confidence in the WRAPSODY CIE device, which received FDA premarket approval in December 2024 and is already commercialized in the US. This is a supportive clinical data update for an already-approved product, not a regulatory catalyst.
Key Facts
- 6-month TLPP for AVF cohort was 92.7% vs 89.8% in WAVE pivotal trial
- 6-month ACPP for AVF cohort was 76.7% vs 72.8% in WAVE trial
- Data presented at CiDA conference on October 31, 2026
- WRAPSODY CIE received FDA premarket approval in December 2024
- US commercialization began January 2025
- WRAP North America registry enrolling up to 250 patients ongoing
Financial Impact
No financial impact stated; product already approved and commercialized. Registry data supports adoption but no revenue or guidance changes.
Risk Factors
- Real-world registry data is non-randomized and may not replicate in broader use
- Competing devices for dialysis access stenosis exist
- No financial guidance or revenue impact provided in this release
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396584 |
Track record
12 reports on MMSI
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +37.91% at T+60 after the May 5, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago Press Release Neutral 3/10 Viewing Entry $89.62 Now $86.35 −3.65% settles Feb 3
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 29, 202618d ago Press Release Neutral 4/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $92.21 Now $86.35 −6.36% settles Jan 26
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $71.09 to $87.00 Now $86.35 +21.47% ▲ +22.38% +18.81% vs SPY
- May 5, 202628w ago Insider Cluster Neutral 3/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- May 5, 202628w ago Insider Cluster Bullish 6/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- Apr 30, 202628w ago Press Release Bullish 7/10 Entry $62.01 to $78.29 Now $86.35 +39.25% ▲ +26.25% +23.18% vs SPY
- Apr 16, 202630w ago Court Ruling Bullish 6/10 Entry $70.10 to $73.26 Now $86.35 +23.18% ▲ +4.51% −2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers